Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion.
作者信息
Rodriguez Nina, Katzenstein Cecilia, Lange Marcia, Rios Jeanette, Kushner Tatyana
机构信息
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
出版信息
J Hepatol. 2025 May 28. doi: 10.1016/j.jhep.2025.05.019.
Abstract
摘要
相似文献
1
Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion.孕期应用代谢相关脂肪性肝病（MASLD）风险算法面临的挑战：呼吁进行调整与纳入。
J Hepatol. 2025 May 28. doi: 10.1016/j.jhep.2025.05.019.
2
Reply to: "Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion".回复：“孕期应用MASLD风险算法面临的挑战：呼吁进行调整与纳入”
J Hepatol. 2025 Aug 5. doi: 10.1016/j.jhep.2025.07.021.
3
Call to action - pediatric MASLD requires immediate attention to curb health crisis.行动呼吁——儿童非酒精性脂肪性肝病相关代谢功能障碍需要立即引起关注，以遏制健康危机。
Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001440.
5
Dietary manganese intake is positively associated with metabolic dysfunction-associated steatotic liver disease: a multicohort study.膳食锰摄入量与代谢功能障碍相关脂肪性肝病呈正相关：一项多队列研究。
Eur J Nutr. 2025 May 26;64(5):188. doi: 10.1007/s00394-025-03708-8.
6
Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: A cohort study.体重减轻和生活方式改变对代谢相关脂肪性肝病（MASLD）和代谢相关脂肪性肝炎（MetALD）肝纤维化的影响：一项队列研究。
Biomed Rep. 2025 Jul 25;23(4):158. doi: 10.3892/br.2025.2036. eCollection 2025 Oct.
7
Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review.2型糖尿病患者代谢功能障碍相关脂肪性肝病的药物治疗选择：一项系统评价
Eur J Clin Invest. 2025 Apr;55(4):e70003. doi: 10.1111/eci.70003. Epub 2025 Feb 12.
8
Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality.颞叶代谢相关脂肪性肝病与2型糖尿病、心血管疾病及死亡率的关联
Cardiovasc Diabetol. 2025 Jul 15;24(1):289. doi: 10.1186/s12933-025-02824-3.
9
Prediction Model for Insulin Resistance and Implications for MASLD in Youth: A Novel Marker, the Pediatric Insulin Resistance Assessment Score.青少年胰岛素抵抗预测模型及其对代谢功能障碍相关脂肪性肝病的意义：一种新型标志物——儿童胰岛素抵抗评估评分
Yonsei Med J. 2025 Aug;66(8):464-472. doi: 10.3349/ymj.2024.0442.
10
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.糖尿病患者的代谢功能障碍相关脂肪性肝病（MASLD）：筛查与早期干预的必要性。美国糖尿病协会共识报告
Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094.
本文引用的文献
1
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.两步临床护理路径在代谢功能障碍相关脂肪性肝病中的预后表现。
J Hepatol. 2025 Jan 23. doi: 10.1016/j.jhep.2025.01.014.
2
Epidemiology of metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的流行病学
Clin Mol Hepatol. 2025 Feb;31(Suppl):S32-S50. doi: 10.3350/cmh.2024.0431. Epub 2024 Aug 19.
3
EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy.EASL 临床实践指南：妊娠与肝病管理。
J Hepatol. 2023 Sep;79(3):768-828. doi: 10.1016/j.jhep.2023.03.006. Epub 2023 Jun 30.
4
Prevalence, Risk Profiles, and National Implications of Nonalcoholic Fatty Liver Disease in Pregnant Individuals.孕妇非酒精性脂肪性肝病的患病率、风险概况及对国家的影响
Clin Gastroenterol Hepatol. 2024 Jan;22(1):194-196.e1. doi: 10.1016/j.cgh.2023.03.031. Epub 2023 Apr 7.
5
Metabolic Dysfunction-Associated Fatty Liver Disease and Subsequent Development of Adverse Pregnancy Outcomes.代谢功能障碍相关脂肪性肝病及其不良妊娠结局的后续发生。
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2542-2550.e8. doi: 10.1016/j.cgh.2021.11.007. Epub 2021 Nov 17.
6
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者风险分层与管理的临床护理路径。
Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20.
7
Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes.妊娠非酒精性脂肪性肝病与不良的母儿围生结局相关。
J Hepatol. 2020 Sep;73(3):516-522. doi: 10.1016/j.jhep.2020.03.049. Epub 2020 Jun 9.
Zotero 插件